Provided herein are poly(ether ester) multi-block copolymers (PEE-MBCP). Also provided herein are injectable delivery systems or pharmaceutical compositions, comprising a PEE-MBCP provided herein, either alone or in combination with a binding protein, such as abicipar. Also provided herein are methods of using these injectable delivery systems or pharmaceutical compositions provided herein for the treatment of ocular disorders.

Biodegradable polymers with advantageous physical and chemical properties are described, as well as methods for making such polymers. In one embodiment, a new chemical synthesis route to technologically important biodegradable poly(3-hydroxybutyrate) (P3HB) with high isotacticity and molecular weight required for a practical use is described. The new route can utilize racemic eight-membered cyclic diolide (rac-DL), meso-DL, or a rac-DL and meso-DL mixture, derived from bio-sourced dimethyl succinate, and enantiomeric (R,R)-DL and (S,S)-DL, optically resolved by metal-based catalysts. With a stereoselective racemic molecular catalyst, the ROP of rac-DL under ambient conditions produces rapidly P3HB with essentially perfect isotacticity ([mm]>99%), high crystallinity and melting temperature (T.sub.m=171° C.), as well as high molecular weight and low dispersity (M.sub.n=1.54×10.sup.5 g/mol, Ð=1.01).

An organic frame material having a cobalt-containing isopoly-molybdic acid metal, a method of manufacturing the same, and applications thereof are provided. The organic frame material having a cobalt-containing isopoly-molybdic acid metal includes a three-dimensional network structure comprising cobalt ions coordinated with 2,3,5,6-tetrafluoro-bis (1,2,4-triazole-1-methyl) benzene ligands and trinuclear molybdate anions. The organic frame material having a cobalt-containing isopoly-molybdic acid metal has higher catalytic activity towards the bulk ring-opening of p-dioxanone. The resulting poly(p-dioxanone) has a weight average molecular weight exceeding 70,000 and is capable of being applied in the field of high polymer materials.

Provided herein are methods and systems for producing biodegradable beta-propiolactone-based polyester polymers from renewable EO and CO on an industrial scale.

Provided herein are methods and systems for producing biodegradable beta-propiolactone-based polyester polymers from renewable EO and CO on an industrial scale.

The invention relates to a polymer comprising: a) at least one polyether polyester copolymer segment, wherein the polyether polyester copolymer comprises ether units selected from the group consisting of the formula (II) —[CR.sup.1.sub.2].sub.n—O—, wherein n is an integer of 2 to 4, R.sup.1 represent independent of each other organic groups having 1 to 30 carbon atoms or hydrogen, and wherein in case n is equal to 2 at least one of the R.sup.1 represents an ether group having the formula —R.sup.2—O—R.sup.3, wherein R.sup.2 and R.sup.3 independent of each other represent organic groups having 1 to 30 carbon atoms, and b) at least one polysiloxane segment linked to the at least one polyether polyester copolymer segment.

The invention relates to a polymer comprising: a) at least one polyether polyester copolymer segment, wherein the polyether polyester copolymer comprises ether units selected from the group consisting of the formula (II) —[CR.sup.1.sub.2].sub.n—O—, wherein n is an integer of 2 to 4, R.sup.1 represent independent of each other organic groups having 1 to 30 carbon atoms or hydrogen, and wherein in case n is equal to 2 at least one of the R.sup.1 represents an ether group having the formula —R.sup.2—O—R.sup.3, wherein R.sup.2 and R.sup.3 independent of each other represent organic groups having 1 to 30 carbon atoms, and b) at least one polysiloxane segment linked to the at least one polyether polyester copolymer segment.

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 3-hydroxyisobutyrate or MAA. Also provided herein are methods for using such an organism to produce 3-hydroxyisobutyrate or MAA.

Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 3-hydroxyisobutyrate or MAA. Also provided herein are methods for using such an organism to produce 3-hydroxyisobutyrate or MAA.